Back to top
more

Tetraphase Pharmaceuticals, Inc. (TTPH)

(Delayed Data from NSDQ)

$1.06 USD

1.06
371,156

+0.07 (7.07%)

Updated May 3, 2019 04:00 PM ET

After-Market: $1.05 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

[TTPH]

Reports for Purchase

Showing records 1 - 20 ( 123 total )

Industry: Medical - Drugs

Record: 1

06/26/2020

Company Report

Pages: 2

The End Part Two-Sell

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 2

06/25/2020

Company Report

Pages: 5

We''re Dizzy...And Is Someone at Tetraphase a Master Negotiator?

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 3

06/23/2020

Company Report

Pages: 2

The Bidding War I s Back On-Hold

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 4

06/05/2020

Company Report

Pages: 5

Melinta Therapeutics to Acquire Tetraphase

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 5

06/05/2020

Company Report

Pages: 2

The End

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 6

06/01/2020

Company Report

Pages: 2

Third Time a Charm for AcelRx?

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 7

05/28/2020

Company Report

Pages: 2

Bidding War Heating Up Hold

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 8

05/19/2020

Company Report

Pages: 2

But Suddenly, A New Contender Has Emerged - Hold

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 9

05/11/2020

Company Report

Pages: 7

1Q20 Recap: Which Offer Will the Board Choose?

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 10

05/07/2020

Company Report

Pages: 2

Overbid Emerges For Tetraphase

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 11

03/17/2020

Company Report

Pages: 2

Opioids - Antibiotics,Together at Last- Sell

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 12

03/13/2020

Company Report

Pages: 6

4Q19 Recap: XERAVA Begins to Gain Traction but Long Road Ahead to Profitability

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 13

02/06/2020

Company Report

Pages: 5

Recent Financings Give XERAVA a Fighting Chance

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 14

01/24/2020

Company Report

Pages: 2

No Solution to Dilution Lowering to Hold - Hold

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 15

11/14/2019

Company Report

Pages: 2

Q3 Results

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 16

11/13/2019

Company Report

Pages: 6

3Q19 Recap XERAVA Growth Would Help, But More Drastic Moves Are Needed

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 17

11/05/2019

Company Report

Pages: 6

Recent Moves Buy Some Time, But Next Two Quarters Are Critical; Maintain Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 18

10/31/2019

Company Report

Pages: 2

A Quiet Takeover?

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 19

10/08/2019

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for TTPH

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 20

10/03/2019

Company Report

Pages: 2

Xerava Growth Slows in Q3 - Hold

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 10.00

Research Provided by a Third Party